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To investigate a potential ligand-dependent transcrip-
tional activation domain (AF-2) in the C-terminal region
of the human vitamin D receptor (hVDR), two conserved
residues, Leu-417 and Glu-420, were replaced with ala-
nines by site-directed mutagenesis (L417A and E420A).
Transcriptional activation in response to 1,25-dihy-
droxyvitamin D3 (1,25-(OH)2D3) was virtually eliminated
when either point mutant was transfected into several
mammalian cell lines. Furthermore, both mutants ex-
hibited a dominant negative phenotype when expressed
in COS-7 cells. Scatchard analysis at 4 °C and a ligand-
dependent DNA binding assay at 25 °C revealed essen-
tially normal 1,25-(OH)2D3 binding for the mutant
hVDRs, which were also equivalent to native receptor in
associating with the rat osteocalcin vitamin D respon-
sive element as a presumed heterodimer with retinoid X
receptor. Glutathione S-transferase-human transcrip-
tion factor IIB (TFIIB) fusion protein linked to Sepha-
rose equally coprecipitated the wild-type hVDR and the
AF-2 mutants. These data implicate amino acids Leu-417
and Glu-420, residing in a putative a-helical region at
the extreme C terminus of hVDR, as critical in the mech-
anism of 1,25-(OH)2D3-stimulated transcription, likely
mediating an interaction with a coactivator(s) or a com-
ponent of the basal transcriptional machinery distinct
from TFIIB.
The actions of the 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3)
1
hormonal ligand are mediated by the vitamin D receptor
(VDR). This nuclear protein belongs to a large superfamily,
which includes receptors for steroids, retinoids, and thyroid
hormone (1). As with other members of this superfamily, the
VDR possesses an N-terminal DNA binding domain (DBD) that
contains two zinc finger DNA binding motifs (2). The C-termi-
nal portion of the VDR contains a ligand binding domain (LBD)
that associates with the 1,25-(OH)2D3 hormone (3). This bind-
ing initiates a presumed conformational change in VDR that
enhances its interaction with any one of several isoforms of
retinoid X receptor (RXR) to form a heterodimer, the apparent
active species in recognizing and binding with high affinity to
vitamin D-responsive elements (VDREs) located in the up-
stream promoter region of genes regulated by 1,25-(OH)2D3 (4,
5). In addition to binding 1,25-(OH)2D3, the C-terminal LBD of
VDR contains residues necessary for heterodimerization with
RXRs (6, 7). When the activated, ligand-bound VDR:RXR het-
erodimer is associated with the VDRE, it stimulates the tran-
scription of downstream target genes (8). Several VDREs have
been characterized to date, with the prototypical sequence con-
sisting of an imperfect direct repeat of six nucleotide bases,
GGGTGA, separated by a 3-base pair spacer (9–13). VDR has
been shown to contact the base pairs in the 39 half-site of the
VDRE, while RXR interacts with the 59 half-site (14).
The precise mechanism of transcriptional regulation by the
activated VDR:RXR heterodimer is not well understood. Func-
tional analyses of members of the nuclear receptor superfamily,
including truncation and point mutagenesis studies, have dem-
onstrated the presence of at least two major domains involved
in receptor-mediated transcriptional stimulation. The N-termi-
nal regions of several nuclear receptors contain a constitutive
activation domain referred to as AF-1 (also designated t1)
(15–17) that can be linked to heterologous DNA binding do-
mains to create functional transcription factors (18–20). More-
over, fusion of the large C-terminal domain of various receptors
to the GAL4 or glucocorticoid receptor (GR) DBD produces a
chimeric protein capable of activating transcription in response
to the cognate ligand (18, 21, 22). A subdomain of this hormone-
dependent, C-terminal activation function is known as AF-2
(also termed t4) (21, 23–25). Unlike the N-terminal AF-1 tran-
scription domain, the C-terminal AF-2 activation unit exhibits
a higher degree of homology among the nuclear receptor super-
family, suggesting a common or related mechanism may be
involved in ligand-mediated gene regulation. In one study (26),
the AF-2 region of the thyroid hormone receptor (TR) was
reported to interact with the basal transcription factor IIB
(TFIIB), implying that association of nuclear receptors with the
basal transcriptional machinery may serve as one means of
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achieving transcriptional control of hormone-stimulated genes.
As part of a preliminary study designed to probe the regions
of VDR involved in heterodimerization, 1,25-(OH)2D3 binding,
and transcriptional activation, our laboratory reported previ-
ously that truncation of the C-terminal 25 amino acids in hVDR
generated a transcriptionally inactive receptor that retained
heterodimerization capacity and also partial ligand binding
ability (6), suggesting the presence of an AF-2 domain in the
extreme C-terminal region of hVDR. In the present study, we
have refined the mapping of this domain by identifying specific
residues essential for competent, hormone-dependent tran-
scriptional activation that are resolved from other biological
activities of the receptor.
EXPERIMENTAL PROCEDURES
Construction of Mutant hVDR Plasmids and Expression in Trans-
fected Cells—The hVDR expression vector, pSG5hVDR (27), was em-
ployed in synthesizing point mutants by in vitro site-directed mutagen-
esis (28). Two residues in the extreme C terminus of hVDR, Leu-417
and Glu-420, were separately altered to alanines (mutants designated
as L417A and E420A, respectively). These mutations were confirmed by
dideoxy sequencing.
Transfection of Cultured Cells and Transcriptional Activation As-
say—COS-7 monkey kidney epithelial cells (700,000 cells/60-mm plate)
were transfected with 0.1 mg of wild-type or mutant hVDR expression
plasmid and 10 mg of a reporter plasmid ((CT4)4-TKGH) containing four
copies of the rat osteocalcin VDRE (13) inserted upstream of the viral
thymidine kinase promoter-growth hormone reporter gene (Nichols In-
stitute, San Juan Capistrano, CA) by the calcium phosphate-DNA co-
precipitation method as described previously (29). The pTZ18U plasmid
was used as carrier DNA, and each transfection contained a constant
amount of total DNA (20 mg). The transfected cells were washed, then
grown in Dulbecco’s modified Eagle’s medium (Life Technologies, Inc.)
supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100
mg/ml streptomycin and various concentrations of 1,25-(OH)2D3 in eth-
anol vehicle. After 24 h of incubation at 37 °C, the level of growth
hormone secreted into the culture medium was assessed by radioim-
munoassay using a commercial kit (Nichols Institute). Transfections
and treatments of HeLa cells and a transformed primary human em-
bryonal kidney cell line (HEK293) were carried out similarly except
these cells were cultured in minimum essential medium supplemented
with 10% fetal bovine serum and antibiotics. Cellular lysates prepared
from transfected cells were analyzed for VDR expression by immuno-
blotting using the 9A7g monoclonal anti-VDR antibody as described
previously (30).
Gel Mobility Shift Assay—Heterodimeric DNA binding activity was
assessed by the gel mobility shift assay essentially as described else-
where (7). In ligand-independent studies, cellular extracts from COS-7
cells transfected with either pSG5 (control) alone, pSG5 containing
wild-type cDNA, or pSG5 containing mutant hVDR cDNAs were incu-
bated with 32P-labeled rat osteocalcin VDRE (59-AGCTGCACTGGGT-
GAATGAGGACATTACA-39; half-sites comprising an imperfect direct
repeat are underlined). In experiments employing the 1,25-(OH)2D3
ligand (31), COS-7 cells were transfected with 50 ng of hVDR expression
plasmids, and the extracts from these cells were initially incubated with
1028 M 1,25-(OH)2D3 for 25 min at 22 °C followed by incubation with the
rat osteocalcin VDRE for 25 min at 22 °C.
1,25-(OH)2D3 Ligand Binding Assay—COS-7 cells transfected with
50 ng of wild-type or mutant hVDR expression plasmids were lysed in
KETZD-0.3 buffer (0.3 M KCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.3
mM ZnCl2, 5 mM dithiothreitol) containing 0.5% Triton X-100 and sup-
plemented with protease inhibitors (2 mg/ml aprotinin, 0.5 mg/ml leu-
peptin, 50 mg/ml trypsin inhibitor). Lysates were tested for 1,25-
(OH)2D3 binding activity as described previously (31).
GST Fusion Protein Binding Assay—Human transcription factor IIB
(hTFIIB)-GST fusion protein was expressed from pGEX-2T-hTFIIB
(26), and GST alone was expressed from pGEX-4T, both in Escherichia
coli strain DH5a. The overexpressed proteins were coupled to glutathi-
one-Sepharose (1 mg of protein/ml of resin) according to the protocol of
the manufacturer (Pharmacia Biotech Inc., Uppsala, Sweden) and
stored as a 50% slurry in KETZD-0.3 containing 30% glycerol at
220 °C. COS-7 cells transfected with either 20 mg of control, wild-type,
or mutant hVDR expression plasmids were resuspended in 550 ml of
KETZD-0.2 (0.2 M KCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.3 mM
ZnCl2, 5 mM dithiothreitol, 1.0 mg/ml bovine serum albumin, 0.2%
Tween 20, 2 mg/ml aprotinin, 0.5 mg/ml leupeptin, 50 mg/ml trypsin
inhibitor) and sonicated on ice. The sonicates were clarified by centrif-
ugation for 15 min at 16,000 3 g at 4 °C, and 500 ml were incubated
with either 20 ml (50% slurry) of hTFIIB-GST-Sepharose or GST-Sepha-
rose alone for 1 h at 4 °C on a rocker tray. The Sepharose beads were
then washed four times with 1 ml each of KETZD-0.2, resuspended in
40 ml of 2 3 final sample buffer (2% SDS, 5% b-mercaptoethanol, 125
mM Tris-HCl, pH 6.8, 20% glycerol) and boiled for 3 min. These samples,
along with 25 ml of original lysate (5% of input) were analyzed for VDR
content by immunoblotting (30).
RESULTS
Conservation of Residues Near the C Terminus of Nuclear
Receptors and Selection of Amino Acids for Site-directed Mu-
tagenesis—The C-terminal LBD of the nuclear receptor super-
family possesses several regions of high homology (32). One
such subdomain, located at the extreme C terminus of the LBD,
is depicted in Fig. 1. Examination of this region of hVDR
reveals Leu-417, which is conserved in the VDR subfamily of
nuclear receptors (VDR, TR, and retinoic acid receptor (RAR)),
as well as in the estrogen receptor (ER), and Glu-420, which is
positionally conserved throughout the superfamily. These two
amino acids probably reside in an a-helical segment of the VDR
based on the recently elucidated three-dimensional crystal
structures of the homologous regions in rat TRa (33), human
RARg (34), and human RXRa (35) LBD. Thus, these residues
were individually altered to alanine in hVDR to preserve the
potential a-helical character in this region and to probe their
potential functional significance.
FIG. 1. Amino acid sequence comparison of the extreme C-
terminal region between VDR and other members of the nu-
clear receptor superfamily. The deduced amino acid sequence of
hVDR between residues 402 and 423 is shown (top) along with the
homologous region in other nuclear receptors. Full-length hVDR con-
tains 427 amino acids, with residues 424–427 being Asn-Glu-Ile-Ser.
Boxed and shaded are the highly conserved leucyl and glutamyl resi-
dues (at positions 417 and 420 in hVDR, respectively), which were
individually mutagenized to alanine. Corresponding a-helical regions in
the recently elucidated crystal structures of rTRa (33), hRARg (34), and
hRXRa (35) are indicated with open bars. AR, androgen receptor; PR,
progesterone receptor.
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Binding of 1,25-(OH)2D3 by VDR Mutants—Considering that
Leu-417 and Glu-420 are located in the LBD, and the residues
corresponding to Val-418 and Phe-422 in VDR (Fig. 1) are
ligand contact sites in either RAR (34) or TR (33), we tested the
1,25-(OH)2D3 ligand binding activity of the above generated
mutant hVDRs in an equilibrium binding assay performed at
4 °C. Extracts from COS-7 cells transfected with expression
plasmids encoding either wild-type or a mutant hVDR were
incubated with increasing concentrations of 1,25-(OH)2D3 over-
night at 4 °C. The data from saturation binding curves (Fig. 2,
A and B) were then transformed and plotted by the method of
Scatchard, yielding an estimate of the dissociation constant
(Kd) for the wild-type and mutant receptors. Results from two
independent experiments (Fig. 2C) revealed that the apparent
Kd for the 1,25-(OH)2D3 ligand is not significantly altered by
replacement of Leu-417 with alanine, at least under the condi-
tions of this standard binding assay. Similarly, only a negligi-
ble increase in the apparent Kd occurs when Glu-420 is altered
to alanine (Figs. 2, B and C). These data extend previous
results (6) that revealed truncation of the last 25 amino acids in
hVDR does not abolish ligand binding but does cause an ap-
proximate 10-fold elevation in the Kd. The extreme C terminus
of hVDR, therefore, is not absolutely required for relatively
high affinity interaction with 1,25-(OH)2D3, suggesting that
this region of the receptor, and more specifically the conserved
residues Leu-417 and Glu-420, performs a different function.
Transcriptional Activation Capacity of Mutant hVDRs in
Transfected Cells—The transcriptional activity of wild-type
and point mutated hVDRs was evaluated in three transfected
cell lines. Fig. 3A illustrates a 1,25-(OH)2D3-stimulated, dose-
dependent increase in transcription of a rat osteocalcin VDRE-
linked reporter gene in transfected COS-7 cells. The maximal
hormone-mediated increase in transcription with the wild-type
receptor in this cell line is approximately 40-fold (at or above
1027 M 1,25-(OH)2D3). Under parallel transfection conditions,
the L417A and E420A hVDRs do not exhibit detectable trans-
activation even at the highest dose (1026 M) of 1,25-(OH)2D3
tested (Fig. 3A). The fact that this pharmacological level of
1,25-(OH)2D3 is ineffective in enhancing transcription (Fig. 3A)
is consistent with the conclusion that the mutant VDRs are not
partially impaired in ligand binding (Fig. 2). Expression of
these mutant hVDRs was similar to that of the wild-type re-
ceptor (data not shown; see also Figs. 4C, 5B, and 6B), elimi-
nating differential expression as a trivial explanation for these
results. To evaluate the possibility that the abrogation of tran-
scriptional activity in these mutant hVDRs is a cell-specific
phenomenon, a similar set of experiments was carried out in a
transformed primary human embryonal kidney cell line
(HEK293; Fig. 3B) and in HeLa cells (Fig. 3C). The maximal
fold increase in transcriptional activity by wild-type hVDR was
FIG. 2. Saturation ligand binding and Scatchard analysis of
hVDR point mutants. Cellular extracts from COS-7 cells transfected
with WT (f) or mutant hVDRs were incubated with increasing concen-
trations of 1,25-(OH)2[
3H]D3 for 16 h at 4 °C. Two representative satu-
ration binding curves, one for L417A (A, l) and one for E420A (B, ),
are shown. Saturation binding data from two independent experiments
were transformed and plotted by the method of Scatchard to yield the
indicated Kd values (C).
FIG. 3. Functional assessment of hVDR C-terminal point mu-
tants. A, COS-7 cells were cotransfected by calcium phosphate-DNA
coprecipitation with expression vectors for either the wild-type (WT) or
mutant hVDRs and a reporter plasmid containing four osteocalcin
VDREs linked to the human growth hormone gene. Cells were treated
for 24 h post-transfection with the indicated amounts of 1,25-(OH)2D3
or ethanol vehicle. The level of growth hormone secreted into the
culture medium, which serves as an index of transcriptional activity,
was assessed by radioimmunoassay. The transcriptional activity of
each receptor species was similarly monitored in a transformed primary
human embryonal kidney cell line, HEK293 (B), and in HeLa cells (C).
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5-fold (Fig. 3B) and 17-fold (Fig. 3C) in HEK293 and HeLa
cells, respectively. The dose-response profile of wild-type hVDR
in these additional cells lines was somewhat similar to that
observed in COS-7 cells, although 1028 M 1,25-(OH)2D3 elicited
a near-maximal transcription effect in HEK293 and HeLa cells,
and 1029 M ligand approximated the ED50 in HeLa cells. Im-
portantly, neither the L417A nor the E420A mutant hVDR
mediates significant ligand-dependent transactivation in these
other two cell lines upon exposure to 1029 M or even 1028 M
1,25-(OH)2D3.
Thus, taken together, the data in Fig. 3 identify residues 417
and 420 in the transactivation function of VDR. A minor but
significant repression of basal transcription is detected in the
case of E420A hVDR, especially in HeLa cells (Fig. 3C), which
is relieved by addition of increasing concentrations of 1,25-
(OH)2D3. This observation is consistent with the findings that
unoccupied nuclear receptors associate with a transcriptional
corepressor that is released by binding of the cognate ligand
(36) and that corepressor interaction may be enhanced by mu-
tation of the receptor AF-2 domain (37). These results support
a model (38) of mutually exclusive binding of a corepressor and
coactivator to overlapping regions in the C termini of nuclear
receptors, a domain that includes Leu-417 and Glu-420.
Transcriptionally Defective VDRs Possess Normal Het-
erodimeric DNA Binding Activity—We next evaluated the abil-
ity of the transcriptionally defective mutant hVDRs to interact
with a prototypical rat osteocalcin VDRE as a heterodimeric
complex with endogenous RXR in transfected COS-7 cells. Ex-
tracts from cells transfected with the wild-type hVDR expres-
sion plasmid form an intense shifted complex when incubated
with the VDRE probe in a gel mobility shift assay (Fig. 4A, lane
2). This retarded band is referred to as VDR:RAF:VDRE be-
cause the exact identity of the receptor auxiliary factor (RAF)
as one of the RXRs is not defined for COS-7 cells. This complex
is absent when extracts from cells transfected with the expres-
sion vector lacking the VDR insert are utilized (lane 1) or when
wild-type VDR-containing extracts are preincubated with anti-
VDR monoclonal antibody 9A7g (lane 3). When extracts from
cells transfected with either the L417A or E420A mutant are
incorporated into this assay (lanes 4 and 5), a shifted complex
of equal intensity and migration position compared with the
wild-type receptor is observed. Thus, there is no evidence to
this point that either mutation in hVDR affects its het-
erodimerization activity, with the caveats that the VDR-con-
taining extracts used in the experiments pictured in Fig. 4A
were obtained from COS-7 cells expressing large amounts of
each receptor protein and, additionally, these cells were not
treated with the 1,25-(OH)2D3 hormone. Thus, a similar anal-
ysis was performed with extracts from COS-7 cells expressing
limiting amounts of VDR, which more closely approximate
levels found in 1,25-(OH)2D3 target tissues, such as bone, in-
testine, or kidney (39). Extracts from these cells were treated
with 1028 M 1,25-(OH)2D3 or ethanol vehicle and used in a
hormone-dependent gel shift assay (31). Under these near
physiologic conditions, wild-type and both hVDR mutants
formed a VDR-containing shifted complex that was enhanced
by the addition of the 1,25-(OH)2D3 ligand (Fig. 4B, compare
lanes 4 with 3, 7 with 6, and 9 with 8). Significantly, the level
of augmentation by 1,25-(OH)2D3 (2-fold) based on densitomet-
ric scanning of the images shown in Fig. 4B (data not shown)
was similar for the wild-type receptor and mutant hVDRs.
Also, the level of expression of each receptor was essentially
equivalent and unmodified by sterol ligand as monitored by
immunoblotting (Fig. 4C). The apparent decrease in VDRE
binding exhibited by the L417A mutant (Fig. 4B, lanes 6 and 7)
is actually the result of less total protein loaded into these lanes
as demonstrated by the decreased intensity of the nonspecific
bands migrating below the hVDR-containing complex. The
nonspecific binding of the two lower complexes was deduced by
their appearance in non-VDR-transfected cells (Fig. 4B, lanes 1
and 2) as well as their lack of elimination by the VDR antibody
(Fig. 4B, lane 5). The level of L417A-containing complex for-
mation approaches that of the wild-type band when corrected
for this loading difference (as assessed by densitometric scan-
ning), and repeat experiments (not shown) indicate that similar
levels of hVDR complexes are formed on the VDRE by all three
hVDRs tested (see also Fig. 4A). Taken together, the results
illustrated in Fig. 4 strongly suggest that the alteration of
Leu-417 or Glu-420 to alanine does not attenuate het-
erodimeric DNA binding by the VDR protein, and such a phe-
FIG. 4. DNA binding activity of wild-type and AF-2 point mu-
tant hVDRs. A, a gel mobility shift assay was performed using extracts
from COS-7 cells transfected with control or hVDR expression plasmids
(1.0 mg) along with a labeled oligonucleotide containing the VDRE from
the rat osteocalcin gene as described under “Experimental Procedures.”
No 1,25-(OH)2D3 ligand was included in these incubations. B, the gel
mobility shift assay was performed as in A except that the COS-7 cells
were transfected with 0.05 mg of the indicated expression plasmid. In
addition, the extracts were incubated with the osteocalcin VDRE either
in the presence of 1028 M 1,25-(OH)2D3 or ethanol vehicle. The anti-
VDR monoclonal antibody (9A7g) is directed against an epitope near
the DNA binding domain and disrupts the interaction of VDR with the
VDRE (60). C, Western blot analysis of the extracts employed in B.
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nomenon cannot therefore account for the paucity of transac-
tivation by these mutants. Additionally, the essentially
equivalent enhancement in VDRE binding elicited by the 1,25-
(OH)2D3 hormone is consistent with the similar Kd values
exhibited by the wild-type and mutant receptors (Fig. 2C).
L417A and E420A hVDRs Act as Effective Dominant Nega-
tive Mutants—Because the above described DNA binding stud-
ies were carried out at nonphysiologic temperatures, in vitro,
with cell extracts, it is not possible to conclude rigorously that
the transcriptionally inactive hVDR mutants actually bind to
the VDRE in intact cells (40, 41). Therefore, we determined
whether the two mutant hVDRs under study could act in a
dominant negative fashion in transactivation assays. Cotrans-
fection experiments in COS-7 cells were designed utilizing the
rat osteocalcin VDRE reporter vector and 0.1 mg of wild-type
hVDR expression plasmid (similar to the experiment shown in
Fig. 3). Under these conditions, the 1,25-(OH)2D3 hormone
results in about a 15-fold increase in transcription of the GH
reporter gene (Fig. 5A, WT). Additional cotransfection of a
5-fold excess (0.5 mg) of L417A or E420A expression plasmid
reduced ligand-dependent transcription by approximately 50%
(L417A) and 66% (E420A), respectively. These results are anal-
ogous to those obtained previously in which a mutant hVDR
possessing an altered T-box region was shown to be an effective
dominant negative at ratios of mutant to wild-type hVDR ex-
pression plasmid of five and greater (42). In rescue experiments
(Fig. 5A), the level of transfected mutant expression vector was
maintained at 0.5 mg, while the amount of wild-type hVDR
expression plasmid was increased to 0.35 mg (designated 11 in
Fig. 5A). The corresponding increase in wild-type hVDR ex-
pression restores 1,25-(OH)2D3-dependent transcriptional acti-
vation to fold effects approaching (WT/E420A, 12X), or even
slightly exceeding (WT/L417A, 19X), the fold effects observed
with transfection of only the wild-type control (WT, 15X). As
expected, immunoblotting of extracts from these transfected
cells revealed a close correlation between the total amount of
VDR receptor plasmid transfected (denoted schematically by
the total number of 1 symbols in each lane, Fig. 5B) and the
level of receptor expression. Because both L417A and E420A
mutant hVDRs retain wild-type levels of hormone and het-
erodimeric DNA binding, in vitro (Figs. 2 and 4), and act in a
dominant negative fashion in transfected cells (Fig. 5), we
conclude that these AF-2 mutants exhibit 1,25-(OH)2D3-de-
pendent binding to the VDRE, in vivo, but as transcriptionally
inactive heterodimers. As demonstrated in Fig. 5A, the expres-
sion of additional wild-type VDR effectively competes with the
mutant receptor for RXR association, and subsequent binding
of a normal heterodimer to the response element leads to en-
hanced activation. In contrast, overexpression of RXRb does
not reverse the dominant negative effect (data not shown),
presumably because the mutated VDR in the heterocomplex
contains an inactive AF-2 domain.
Wild-type and Mutant hVDRs Interact with Human TFIIB,
in Vitro—Recently, it has been reported that the VDR interacts
physically and functionally with the general transcription fac-
tor IIB in a 1,25-(OH)2D3 ligand-independent fashion (43, 44).
In one of these reports, it was suggested that the extreme
C-terminal portion of VDR may represent a contact domain for
TFIIB (44), an observation also reported for TFIIB interaction
with TR (26). Consequently, we probed the potential interac-
tion of L417A and E420A with TFIIB, in vitro, to determine if
a lack of TFIIB association could explain the transcriptionally
defective and dominant negative phenotypes of these mutant
receptors. Extracts from COS-7 cells transfected with expres-
sion plasmids for each receptor protein were incubated in the
absence of the 1,25-(OH)2D3 ligand (Fig. 6A) with hTFIIB-GST
fusion protein linked to glutathione-Sepharose beads (GST-
TFIIB-S) or GST-Sepharose (GST-S) as a control (Fig. 6A).
After extensive washing, the presence of VDR protein copre-
cipitated by the GST-TFIIB-S or GST-S complex was detected
by immunoblotting using an anti-VDR monoclonal antibody.
The results illustrate that wild-type VDR (Fig. 6A, lane 4), as
well as both mutant hVDRs (Fig. 6A, lanes 6 and 8), interact
efficiently and specifically with TFIIB; similar results were
obtained in the presence of 1028 M 1,25-(OH)2D3 (data not
shown). The levels of VDR protein were essentially equivalent
as verified by Western blot analysis (Fig. 6B) using 5% of the
total extracts from the experiment illustrated in Fig. 6A. These
data argue against a role for Leu-417 and/or Glu-420 in
contacting TFIIB.
DISCUSSION
Previously, we reported that the C-terminal 25 amino acids
of hVDR appeared to be vital for hormone-dependent transac-
tivation (6). It is now demonstrated that two well conserved
amino acids within this region of hVDR (Fig. 1), Leu-417 and
Glu-420, are essential for 1,25-(OH)2D3 ligand-stimulated tran-
scription (Fig. 3) and likely define the AF-2 function in the
VDR. Because mutation of these residues does not affect hor-
FIG. 5. Analysis of the dominant negative effect of L417A and
E420A. A, COS-7 cells were cotransfected with 10 mg of the (CT4)4-
TKGH reporter vector and 0.1 mg (1) WT hVDR expression plasmid in
combination with 0.5 mg (1) of a vector encoding the L417A or E420A
mutant hVDRs as described under “Experimental Procedures.” In res-
cue experiments, the level of WT hVDR expression plasmid transfected
was increased to 0.35 mg (11). All cells were transfected with a con-
stant total amount of pSG5 parent expression vector. Cells were treated
for 24 h post-transfection with 1028 M 1,25-(OH)2D3 or ethanol vehicle.
The level of growth hormone secreted into the culture medium serves as
an index of transcriptional activity and was assessed by radioimmuno-
assay. The suppression in transactivation elicited by either mutant
receptor can be reversed by expression of additional wild-type hVDR
(11). B, Western blot of cellular extracts prepared from cells trans-
fected in A. Note that the migration position of L417A or E420A is the
same as WT hVDR and that the signal increases with transfection of
additional amounts of hVDR expression plasmid.
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mone (Fig. 2) or DNA binding (Fig. 4) to any significant degree,
these amino acids are thought to participate directly in the
mechanism of transcriptional activation following the recruit-
ment of ligand-bound VDR:RXR heterodimers to the VDRE.
Such a mechanism might involve the interaction of VDR with
basal or TATA-binding protein-associated factors, thus facili-
tating the formation of an active transcriptional complex. VDR
also physically interacts with TFIIB (43), and inferences from
studies utilizing TR and VDR (26, 44) suggested that the C
terminus of these receptors might be involved in TFIIB inter-
action. However, the fact that the wild-type receptor and both
mutant VDRs interact similarly with TFIIB, in vitro (Fig. 6),
argues against any interaction between these residues and
TFIIB. Rather, the present results suggest that Leu-417 and
Glu-420 represent contact sites for the interaction of VDR with
another coactivator protein(s) required for ligand-dependent
transcriptional stimulation. Further studies of wild-type and
AF-2 mutant VDRs employing methodologies such as the yeast
two-hybrid system will be required to identify proteins which
physically and functionally associate with this region of VDR.
Other members of the nuclear receptor superfamily also
possess a transactivation domain in the C-terminal region. The
chicken TRa has been shown to contain a ligand-dependent
activation function in the last 35 amino acids of the receptor
(45), and within this domain several acidic and hydrophobic
residues were found to be critical for transcriptional activity.
Interestingly, this region of the protein is absent in the tran-
scriptionally defective v-erbA protein, the viral homolog of
cTRa. Similar results have been reported for the human TRb1,
where mutations in the two residues corresponding to Leu-417
and Glu-420 generated receptors with wild-type hormone and
DNA binding activity but abrogated transactivation (46, 47), a
phenotype shared by the present hVDR mutants. In addition,
point mutagenesis of the mouse RARa1 and truncation analy-
sis of mouse RXRa have also revealed the importance of this
domain in gene activation in these and other receptors (25, 48),
an observation consistent with the relatively high level of con-
servation of this region among the nuclear receptor superfam-
ily (Fig. 1). In fact, it appears that the homologous amino acids
identified in the present study for VDR may be essential for
transactivation even in the more distantly related ER and GR
(23, 49), although in one study (23), mutation of the residue in
mouse ER (E546A) corresponding to Glu-420 in hVDR only
modestly affected transcriptional activation. In contrast, an
E546A mutant that also lacked the ER AF-1 domain could not
stimulate transcription. These results suggest that the previ-
ously described synergism between AF-1 and AF-2 (19) might
depend on the presence of Glu-546 in ER. If the VDR, with its
relatively small N terminus, lacks an AF-1 region, this could
explain the almost complete abolishment of transcriptional
activity when Glu-420 is mutated in hVDR, while the ER
E546A mutant still possesses significant activity. The impor-
tance of the AF-2 region in the nuclear receptor superfamily is
further supported by the observation that ER and RXR trun-
cation mutants (41, 49) and a deletion mutant of RARa (48), all
of which are missing amino acids homologous to Leu-417 and
Glu-420 in hVDR, act as effective dominant negative receptors
similar to the hVDR mutants described herein (Fig. 5). The
concept of a dominant negative phenotype for AF-2 mutants
(34), including those in the VDR, is in agreement with wild-
type hormone and dimeric DNA binding properties exhibited
by these altered receptors, since this would allow the mutants
to form inactive dimers that compete with the wild-type protein
for binding to the cognate responsive elements, thereby sup-
pressing gene stimulation.
The recently described crystal structures for the hormone
binding domains of rTRa (33), hRARg (34), and hRXRa (35)
indicate that all three receptors share a large degree of a-hel-
ical content, with many of the helices being generally conserved
within the overall structure of the protein. In particular, the
terminal a-helix in all three molecules (Fig. 1, a-helix 12)
encompasses the conserved region that contains Leu-417 and
Glu-420. It has been postulated that this a-helical segment
projects away from the core of the LBD and that hormone
binding induces a conformational change in the receptor caus-
ing the repositioning of helix 12 so that it essentially covers the
opening of the ligand binding pocket. This hypothesis, termed
the “mouse trap” model (34), further predicts that Glu-414 in
hRARg (homologous to Glu-420 in hVDR) forms a crucial salt
bridge with Lys-264 (homologous to Lys-264 in hVDR) which is
thought to “lock” helix 12 in a position over the ligand binding
pocket following interaction of the receptor with its cognate
hormone. Additionally, this conformational change appears to
place helix 12 in a position to effectively interact with a coac-
tivator protein. Mutation of either partner in this putative salt
bridge in hRARg (34) abolishes transactivation and results in a
receptor with the dominant negative phenotype. In preliminary
experiments with hVDR,2 a theoretical hVDR salt bridge “re-
versal” double mutant (K264E-E420K), which would be pre-
dicted to preserve the putative electrostatic bond, was found to
be inactive transcriptionally. Thus, Lys-264 in hVDR does not
2 P. W. Jurutka, L. S. Remus, and M. R. Haussler, unpublished
observations.
FIG. 6. Interaction of hVDR AF-2 mutants with human tran-
scription factor IIB (hTFIIB). A, extracts from COS-7 cells trans-
fected with control or hVDR expression plasmids (5.0 mg) were incu-
bated with either a glutathione S-transferase (GST)-hTFIIB fusion
protein bound to Sepharose beads (GST-hTFIIB-S) or GST alone bound
to Sepharose (GST-S) for 1 h at 4 °C. The beads were then washed
extensively, and the amount of precipitated WT or mutant hVDR pro-
tein was detected by electrophoresis of denatured samples extracted
from the beads, followed by immunoblotting. The amount of extract
analyzed by Western blotting as input (B) was 5% of the amount used
in the coprecipitation reactions (A).
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appear to form a salt bridge with Glu-420, but this does not
exclude potential electrostatic bonds between Glu-420 and
other positively charged VDR residues or the existence of a
novel salt bridge capable of positioning the VDR AF-2 to seal
the ligand binding pocket.
The proposed role of the AF-2 region in providing a protein-
protein interaction surface for contacting a coactivator is sup-
ported not only by the three-dimensional crystal structures of
hRARg, rTRa, and hRXRa as discussed above, but also by the
recent identification of candidate coactivator proteins for vari-
ous nuclear receptors. The ER, for example, has been shown to
interact with a 160-kDa protein in an estrogen- and AF-2-de-
pendent manner (50). Another protein, SPT6, appears to phys-
ically interact with the C-terminal portion of ER and to en-
hance ER-dependent transactivation (51). Moreover, the
nuclear protein RIP140 also associates with and enhances ER
activity in the presence of estrogen but not the antagonist,
4-hydroxytamoxifen (52). In this latter study, the interaction of
hormone-occupied ER with RIP140 was abolished by mutations
in the ER AF-2 that abrogated transcriptional activation (in
the absence of AF-1), including a point mutant at residue 546
(homologous to hVDR Glu-420). Other candidate coactivators
include GRIP1 (53), which interacts with ER, GR, and the
androgen receptor, and steroid receptor coactivator-1 (54),
which stimulates the transcriptional activity of several nuclear
receptors. In each case, the interaction between the putative
coactivator and the receptor protein requires residues in the
AF-2-containing LBD. Preliminary data3 with hVDR AF-2 mu-
tants indicate that both 1,25-(OH)2D3 ligand and an intact
AF-2 are required for squelching of dexamethasone/GR/glu-
cocorticoid responsive element-mediated transcription in
COS-7 cells. These results suggest that the AF-2 domain of
hVDR (Fig. 1, a-helix 12), including residues Leu-417 and Glu-
420, likely represents a docking site for a general nuclear
receptor coactivator, possibly including one or more of those
proteins described above. In addition, given that some amino
acid variation in this region exists between the nuclear recep-
tors (Fig. 1), several residues in this domain may constitute a
“coactivator code” that dictates receptor-specific coactivator in-
teractions in certain cell types.
Analogous to other ligand-activated nuclear receptors, VDR
apparently exists in a monomeric, inactive conformation with
the C-terminal AF-2 presumably extended away from the hor-
mone binding cavity. We propose that upon binding 1,25-
(OH)2D3 in target cell nuclei (55), VDR assumes an active
conformation as the AF-2 is repositioned for both ligand reten-
tion and coactivator contact, with Leu-417 and Glu-420 being
critical for this latter association. In addition, the hormone
facilitates interaction of VDR and RXR through a stabilized
heterodimerization interface mediated by other regions within
the VDR C-terminal hormone binding domain (6, 7). The VDR
partner, RXR, also possesses an AF-2 (Fig. 1 and Ref. 25) that
participates in transcriptional activation by 1,25-(OH)2D3
through association with a distinct coactivator. This interpre-
tation is supported by the fact that C-terminally truncated
RXRs function as dominant negative partners in VDR-medi-
ated transcription (41). Additionally, based upon a previous
study (5), it is speculated (56) that the AF-2 in RXR has the
ability to be positioned for transactivation in the absence of its
9-cis-retinoic acid ligand, likely via allosteric modulation by
1,25-(OH)2D3-occupied VDR in the RXR:VDR heterodimer.
Therefore, the mechanism of VDR action is proposed to be
similar to that of TR (57, 58), where liganding of only the
primary receptor and not the RXR heteropartner is sufficient to
elicit maximal transcriptional stimulation via the AF-2s of both
receptors. This differs from the function of RXR:RAR het-
erodimers (59), in which the liganding of both partner receptors
yields responsive element occupation, in vivo, and full tran-
scriptional activation by the cooperation of AF-2s. The avail-
ability of VDR AF-2 mutants presented herein will facilitate
the isolation of VDR-specific coactivators, which should help to
define further the mechanistic diversity of action among the
VDR/TR/RAR subfamily.
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